US6147089A
(en)
*
|
1998-09-17 |
2000-11-14 |
Pfizer Inc. |
Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
|
GT199900147A
(es)
*
|
1998-09-17 |
1999-09-06 |
|
1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
|
US6197786B1
(en)
*
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
US7115279B2
(en)
*
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
SE0101161D0
(sv)
|
2001-03-30 |
2001-03-30 |
Astrazeneca Ab |
New compounds
|
AU2002320025A1
(en)
*
|
2001-04-11 |
2002-11-11 |
Atherogenics, Inc. |
Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
|
CZ20032900A3
(cs)
|
2001-04-30 |
2004-06-16 |
Pfizer Products Inc. |
Sloučeniny vhodné jako meziprodukty
|
EE200400024A
(et)
*
|
2001-06-21 |
2004-06-15 |
Pfizer Products Inc. |
Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
|
JP2004534812A
(ja)
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
薬物および中性ポリマーの分散物の医薬組成物
|
DE60238193D1
(de)
|
2001-06-22 |
2010-12-16 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
|
EP1269994A3
(de)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
MXPA04005864A
(es)
*
|
2001-12-19 |
2004-10-29 |
Atherogenics Inc |
Derivados de charcona y su uso para tratar enfermedades.
|
US7202247B2
(en)
|
2001-12-19 |
2007-04-10 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
CZ2004747A3
(cs)
*
|
2001-12-21 |
2004-11-10 |
Novo Nordisk A/S |
Deriváty amidů jako GK aktivátory
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
JP2005523262A
(ja)
|
2002-02-01 |
2005-08-04 |
ファイザー・プロダクツ・インク |
薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
|
JP4865989B2
(ja)
*
|
2002-02-01 |
2012-02-01 |
ベンド・リサーチ・インコーポレーテッド |
改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
|
BR0307332A
(pt)
*
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
|
MXPA05000130A
(es)
*
|
2002-06-27 |
2005-02-17 |
Novo Nordisk As |
Derivados de aril-carbonilo como agentes terapeuticos.
|
US7071210B2
(en)
*
|
2002-07-02 |
2006-07-04 |
Pfizer Inc. |
CETP inhibitors in combination with antihypertensive agents and uses thereof
|
US20040053842A1
(en)
*
|
2002-07-02 |
2004-03-18 |
Pfizer Inc. |
Methods of treatment with CETP inhibitors and antihypertensive agents
|
US7504508B2
(en)
|
2002-10-04 |
2009-03-17 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
US20090181966A1
(en)
*
|
2002-10-04 |
2009-07-16 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
BR0315041A
(pt)
*
|
2002-10-04 |
2005-08-16 |
Millennium Pharm Inc |
Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
|
EP1556356B1
(de)
*
|
2002-10-21 |
2006-05-31 |
Warner-Lambert Company LLC |
Tetrahydrochinolin-derivate als crth2 antagonisten
|
AU2003289207A1
(en)
*
|
2002-12-06 |
2004-06-30 |
Kyowa Hakko Kogyo Co., Ltd. |
Anti-inflammatory agent
|
US20040181075A1
(en)
*
|
2002-12-19 |
2004-09-16 |
Weingarten M. David |
Process of making chalcone derivatives
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
ATE407670T1
(de)
|
2002-12-20 |
2008-09-15 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
|
EP1435356A1
(de)
*
|
2003-01-06 |
2004-07-07 |
Warner-Lambert Company LLC |
Chinolinderivate als CRTH2-Antagonisten
|
WO2004072042A2
(en)
*
|
2003-02-12 |
2004-08-26 |
Carex S.A. |
Quinoline derivative and their use for modulation of lxr activity
|
NZ542852A
(en)
|
2003-03-17 |
2008-09-26 |
Japan Tobacco Inc |
Pharmaceutical compositions of CETP inhibitors
|
CA2519458A1
(en)
*
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
|
AU2004224082A1
(en)
*
|
2003-03-28 |
2004-10-07 |
Pfizer Products Inc. |
1,2,4-substitute 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as CETP inhibitors for the treatment of atherosclerosis and obesity
|
US20040204450A1
(en)
*
|
2003-03-28 |
2004-10-14 |
Pfizer Inc |
Quinoline and quinoxaline compounds
|
TWI393560B
(zh)
*
|
2003-05-02 |
2013-04-21 |
Japan Tobacco Inc |
包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
|
NZ543741A
(en)
|
2003-05-30 |
2009-10-30 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as HMG-Co inhibitors
|
BRPI0413277A
(pt)
|
2003-08-04 |
2006-10-10 |
Pfizer Prod Inc |
composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
|
CL2004001884A1
(es)
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
RU2330682C2
(ru)
|
2003-09-26 |
2008-08-10 |
Джапан Тобакко Инк. |
Способ ингибирования продуцирования остаточных липопротеинов
|
JP2007507481A
(ja)
*
|
2003-09-30 |
2007-03-29 |
ファイザー・プロダクツ・インク |
Cetp阻害薬及びその代謝産物
|
EP2098512A1
(de)
*
|
2003-10-08 |
2009-09-09 |
Eli Lilly & Company |
Verbindungen und Verfahren zur Behandlung von Dyslipidämie
|
DE602004020649D1
(de)
*
|
2003-11-07 |
2009-05-28 |
Jj Pharma Inc |
Hdl-verstärkende kombinationstherapie-komplexe
|
CA2551324C
(en)
*
|
2004-01-06 |
2012-11-27 |
Novo Nordisk A/S |
Heteroaryl-ureas and their use as glucokinase activators
|
ES2399721T5
(es)
|
2004-03-05 |
2016-05-25 |
Univ Pennsylvania |
Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
ATE402180T1
(de)
|
2004-03-26 |
2008-08-15 |
Lilly Co Eli |
Verbindungen zur behandlung von dyslipidemie
|
MY139887A
(en)
*
|
2004-04-02 |
2009-11-30 |
Mitsubishi Tanabe Pharma Corp |
Tetrahydronaphthyridine derivatives and a process for preparing the same.
|
UA90269C2
(ru)
*
|
2004-04-02 |
2010-04-26 |
Мицубиси Танабе Фарма Корпорейшн |
Тетрагидрохинолиновые производные и способ их получения
|
US20050282812A1
(en)
*
|
2004-06-18 |
2005-12-22 |
JONES Zachary |
Inhibitors of cholesteryl ester transfer protein
|
WO2006012093A1
(en)
*
|
2004-06-24 |
2006-02-02 |
Eli Lilly And Company |
Compounds and methods for treating dyslipidemia
|
KR100859223B1
(ko)
*
|
2004-06-24 |
2008-09-18 |
일라이 릴리 앤드 캄파니 |
이상지혈증 치료를 위한 화합물 및 방법
|
US20060063828A1
(en)
*
|
2004-06-28 |
2006-03-23 |
Weingarten M D |
1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
EP2208496A1
(de)
*
|
2004-08-25 |
2010-07-21 |
Essentialis, Inc. |
Pharmazeutische Formulierungen von Kalium-ATP-Kanalöffnern und deren Verwendungen
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
US20070149567A1
(en)
*
|
2004-09-23 |
2007-06-28 |
Pfizer Inc |
Quinoline compounds
|
ATE439347T1
(de)
*
|
2004-11-23 |
2009-08-15 |
Warner Lambert Co |
7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
|
WO2006069162A1
(en)
*
|
2004-12-20 |
2006-06-29 |
Reddy Us Therapeutics, Inc. |
Novel heterocyclic compounds and their pharmaceutical compositions
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
EP1848430B1
(de)
|
2004-12-31 |
2017-08-02 |
Dr. Reddy's Laboratories Ltd. |
Neue benzylaminderivate als cetp-inhibitoren
|
US8617604B2
(en)
|
2005-02-03 |
2013-12-31 |
Bend Research, Inc. |
Pharmaceutical compositions with enhanced performance
|
MX2007010215A
(es)
|
2005-02-24 |
2007-11-07 |
Millennium Pharm Inc |
Antagonistas del receptor pgd2 para el tratamiento de enfermedades inflamatorias.
|
WO2006098394A1
(ja)
*
|
2005-03-14 |
2006-09-21 |
Japan Tobacco Inc. |
脂質吸収抑制方法および脂質吸収抑制剤
|
AU2006265975B2
(en)
*
|
2005-07-01 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Process for synthesizing a CETP inhibitor
|
EP1904466A1
(de)
*
|
2005-07-08 |
2008-04-02 |
Novo Nordisk A/S |
Dicycloalkyl-harnstoff-glucokinase-aktivatoren
|
WO2007006761A1
(en)
*
|
2005-07-08 |
2007-01-18 |
Novo Nordisk A/S |
Dicycloalkylcarbamoyl ureas as glucokinase activators
|
JP4960355B2
(ja)
|
2005-07-14 |
2012-06-27 |
ノボ・ノルデイスク・エー/エス |
ウレア型グルコキナーゼ活性化剤
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
JP4681526B2
(ja)
*
|
2005-09-29 |
2011-05-11 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP4531027B2
(ja)
*
|
2005-09-29 |
2010-08-25 |
田辺三菱製薬株式会社 |
医薬組成物
|
CN101291662A
(zh)
|
2005-10-21 |
2008-10-22 |
诺瓦提斯公司 |
肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
|
US8026377B2
(en)
|
2005-11-08 |
2011-09-27 |
Ranbaxy Laboratories, Limited |
Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
CN103172592B
(zh)
|
2006-01-05 |
2016-01-06 |
伊森舍丽斯有限公司 |
钾atp 通道开放剂的盐及其用途
|
UY30117A1
(es)
|
2006-01-31 |
2007-06-29 |
Tanabe Seiyaku Co |
Compuesto amina trisustituido
|
PE20071025A1
(es)
|
2006-01-31 |
2007-10-17 |
Mitsubishi Tanabe Pharma Corp |
Compuesto amina trisustituido
|
UY30244A1
(es)
|
2006-03-30 |
2007-11-30 |
Tanabe Seiyaku Co |
Un proceso para preparar derivados de tetrahidroquinolina
|
GB0615670D0
(en)
*
|
2006-08-07 |
2006-09-13 |
Syngenta Participations Ag |
Chemical compounds
|
US7750019B2
(en)
|
2006-08-11 |
2010-07-06 |
Kowa Company, Ltd. |
Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
|
TW200831497A
(en)
*
|
2006-10-12 |
2008-08-01 |
Epix Delaware Inc |
Carboxamide compounds and their use
|
ATE547394T1
(de)
|
2006-12-01 |
2012-03-15 |
Bristol Myers Squibb Co |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
|
JP2010513534A
(ja)
*
|
2006-12-21 |
2010-04-30 |
エージェリオン ファーマシューティカルズ, インコーポレイテッド |
Mtpインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
|
WO2008084043A1
(en)
*
|
2007-01-09 |
2008-07-17 |
Novo Nordisk A/S |
Urea glucokinase activators
|
US8318778B2
(en)
|
2007-01-11 |
2012-11-27 |
Novo Nordisk A/S |
Urea glucokinase activators
|
CN101220021B
(zh)
*
|
2007-01-12 |
2010-12-08 |
上海医药工业研究院 |
4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
|
US7790737B2
(en)
|
2007-03-13 |
2010-09-07 |
Kowa Company, Ltd. |
Substituted pyrimidine compounds and their utility as CETP inhibitors
|
MX2009010962A
(es)
|
2007-04-13 |
2009-12-16 |
Kowa Co |
Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
|
JP2010532383A
(ja)
*
|
2007-07-02 |
2010-10-07 |
エッセンシャリス,インク. |
カリウムatpチャネル開口薬の塩およびその使用
|
WO2009059943A1
(en)
|
2007-11-05 |
2009-05-14 |
Novartis Ag |
4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
|
PL2229356T3
(pl)
|
2007-12-03 |
2012-03-30 |
Novartis Ag |
1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
|
US8569282B2
(en)
|
2007-12-11 |
2013-10-29 |
Cytopathfinder, Inc. |
Carboxamide compounds and their use
|
BRPI1010600A2
(pt)
|
2009-05-15 |
2016-03-15 |
Novartis Ag |
aril piridina como inibidores de aldosterona sintase
|
AU2010247391A1
(en)
|
2009-05-15 |
2011-12-01 |
Novartis Ag |
Benzoxazolone derivatives as aldosterone synthase inhibitors
|
EA019511B1
(ru)
|
2009-05-28 |
2014-04-30 |
Новартис Аг |
Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
|
MA33364B1
(fr)
|
2009-05-28 |
2012-06-01 |
Novartis Ag |
Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
|
TWI450896B
(zh)
*
|
2009-06-30 |
2014-09-01 |
Lilly Co Eli |
反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸
|
EP2993169B1
(de)
|
2009-11-17 |
2017-12-20 |
Novartis AG |
Aryl-pyridin derivate als aldosteron synthase hemmer
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
EP2507234B1
(de)
|
2009-11-30 |
2014-03-12 |
Novartis AG |
Imidazolderivate als aldosteron-synthasehemmer
|
CA2799708A1
(en)
|
2010-05-21 |
2011-11-24 |
Pfizer Inc. |
2-phenyl benzoylamides
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
EP2668507B1
(de)
|
2011-01-26 |
2017-08-23 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren zur prüfung des risikos einer herz-kreislauf-erkrankung eines patienten
|
US20130345392A1
(en)
|
2011-03-04 |
2013-12-26 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
ES2613644T3
(es)
|
2011-06-17 |
2017-05-25 |
Merck Sharp & Dohme Corp. |
Tetrahidroquinolinas condensadas con cicloalquilo como moduladores del receptor CRTH2
|
TWI537262B
(zh)
*
|
2011-08-17 |
2016-06-11 |
美國禮來大藥廠 |
供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
|
WO2013024358A2
(en)
|
2011-08-18 |
2013-02-21 |
Dr. Reddy's Laboratories Ltd. |
Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
|
WO2013046045A1
(en)
|
2011-09-27 |
2013-04-04 |
Dr. Reddy's Laboratories, Ltd. |
5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
SI2956464T1
(en)
|
2013-02-14 |
2018-08-31 |
Novartis Ag |
Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (neutral endopeptidases)
|
SG11201507496UA
(en)
|
2013-04-17 |
2015-11-27 |
Pfizer |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
SG11201600211XA
(en)
|
2013-07-25 |
2016-02-26 |
Novartis Ag |
Cyclic polypeptides for the treatment of heart failure
|
UY35671A
(es)
|
2013-07-25 |
2015-02-27 |
Novartis Ag |
Bioconjugados de polipéptidos de apelina sintética
|
CN107072999A
(zh)
|
2014-08-28 |
2017-08-18 |
狄智玛制药私人有限公司 |
包含胆固醇酯转运蛋白抑制剂和HMG CoA还原酶抑制剂的药物组合物和治疗组合
|
CA2959208C
(en)
|
2014-08-29 |
2023-09-19 |
Tes Pharma S.R.L. |
Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
MA41580A
(fr)
|
2015-01-23 |
2017-11-29 |
Novartis Ag |
Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
EP3806852A1
(de)
|
2018-06-12 |
2021-04-21 |
vTv Therapeutics LLC |
Therapeutische verwendung von glucokinaseaktivatoren in kombination mit insulin oder insulinanaloga
|
SG11202107614PA
(en)
|
2019-01-18 |
2021-08-30 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|